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ABSTRACT

A method for the qualitative assessment of oxidative

drug metabolism de?ciencies, preferably for the qualita
tive assessment of dextromethorphan metabolism, in a

subject comprises analyzing a sample ?uid from the
subject, for example urine, which contains metabolites
of a probe drug using high performance thin layer chro

matography.

8 Claims, No Drawinm
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chelbaum et al, Xenobiotica, Vol. 16, No. 5 (1986), pages

465-481 (gas chromatography).
Additionally, determinations of dextromethorphan

QUALITATIVE METABOLISM ASSESSMENT
USING HIGH PERFORMANCE THIN LAYER
CHROMATOGRAPHY

and its metabolites using high pressure liquid chroma
tography suitable for use in pharmacogenetic screening
procedures are disclosed by Park et al, Journal of Phar
maceulical Sciences, Vol. 73, No. 1 (1984), pages 24-29;
Achari et al, Journal ofPharmaceutical Sciences, -Vol. 73,
No. 12 (1984), pages 1821-1822; and East et al, Journal
of Chromatography, 338 (1985), pages 99-112.

FIELD OF THE INVENTION
The present invention relates to a method for the

qualitative assessment of oxidative drug metabolism
de?ciencies in a subject. The subject may be human or
a nonhuman animal. The present invention further re
lates to a method for the qualitative assessment of dex

BACKGROUND OF THE INVENTION

While gas chromatography and high performance
liquid chromatography are advantageous in providing
quantitative analyses of oxidative drug metabolism dur
ing pharmacogenetic screening, these methods are dis

Interest in the pharmacogenetics of oxidative drug
metabolism has grown rapidly in the past several years.

advantageous in that they require complex, expensive
equipment, including chromatographic columns, and in

tromethorphan metabolism in a subject.

that they are time consuming. For example, in a typical
arrangement, a high pressure liquid chromatography
causes the subjects to act as a slow or poor metabolizer 20 apparatus permits only one analysis per ten minute per
iod. Thus, a need exists for a faster method of analysis in
rather than a fast, ef?cient or extensive metabolizer of
pgenetic screening of oxidative drug metabo
certain drugs. Several drugs have been used as probes
lisms. A. need also exists for such a method of analysis
for the assessment of oxidative drug metabolism de?
which uses more simple and inexpensive equipment
ciencies in subjects, including dextromethorphan, de
than that required in the gas and high performance
brisoquine and sparteine. See, for example, Kupfer et al,
It has been discovered that a genetic de?ciency in oxi
dative drug metabolism exists in certain subjects which

liquid chromatography techniques.

“Dextromethorphan as a Safe Probe for Debrisoquine

Hydroxylation Polymorphism”, The Lancet (Sept. 1,
1984), pages 517-518; Roy et al, “Methoxyphenamine

SUMMARY OF THE INVENTION
It is therefore an object of the present invention to
quine Hydroxylation Polyamorphism”, The Lancet 30 provide a method for the assessment of oxidative drug
metabolisms which is both more time ef?cient and inex
(Dec. 15, 1984), page 1393; Schmid et a1, “Polymorphic
Dextromethorphan Metabolism: (Jo-Segregation of pensive as compared with prior known methods. It is a
more speci?c object of the present invention to provide
Oxidative O-Demethylation with Debrisoquine Hy
a method for the
ment of oxidative drug metabo
droxylation”, Clinical Pharmacology and Therapeutics,
lism de?ciencies which is both time ef?cient and inex
Vol. 38, No. 6 (1985), pages 618-624; De Zeeuw et al,

and Dextromethorphan as Safe Probes for Debriso

“Interindividual Differences in Dextromethorphan Ki
netics in Man”, Acta Pharmacologica et Toxicologica,
Vol. 59, Supplement V (1986), page 44; and Kupfer et
al, “Pharmacogenetics of Dextromethorphan O-Demet
hylation in Man”, Xenobiotica, Vol. 16, No. 5 (1986), 40

pensive.

pages 421-433, for ?irther details of previous studies in

pensive pharmacogenetic screening procedures and

this regard.

phenotyping procedures. It is a further object of the
present invention to provide a method for the qualita

'

"

Generally, pharmacogenetic screening using the

It is a further object of the present invention to pro
vide a method for the qualitative assessment of oxida

tive drug metabolism, particularly oxidative drug me
tabolism de?ciencies, for use in time ef?cient and inex

aforementioned or other drugs as probes has been con
tive assessment of dextromethorphan metabolism which
ducted by administering the probe drug to a subject and 45 may be performed both rapidly and economically.
These and additional objects are provided according
then quantitatively monitoring a. body ?uid containing
to the present invention which generally comprises a
metabolites of the probe drug. Known methods for
method for the qualitative assessment of oxidative drug
analyzing body ?uids such as urine containing the drug

and its metabolites include gas chromatography and

high performance liquid chromatography. Both gas
chromatography and high performance liquid chroma
tography provide a quantitative indication of the rela
tive amounts of the probe drug and the metabolites of
the probe drug in the sampled body ?uid. The gas chro

metabolism de?ciencies in a subject. The method com
50

prises analyzing a sample ?uid from the subject, for
example urine, which contains metabolites of a probe

drug using high performance thin layer chromatogra
phy. A probe drug may be de?ned as a drug which is
administered to a subject in a controlled amount in

matography and high performance liquid chromatogra

55 order to investigate metabolic characteristics of the

phy method are‘ particularly suitable for determining
the relative amounts of the substances. Reports of phar

mance thin layer chromatography is classi?ed under the

macogenetic screenings using either gas chromatogra
phy or high performance liquid chromatography tech

matography and is generally known in the art. See, for

subject with respect to the probe drug. High perfor
general category of adsorption and/or partition chro»

niques are disclosed by, for example, Price Evans et al,
Journal of Medical Genetics, 17 (1980), pages 102-105

example, Practice of Thin Layer Chromatography, Sec»

(gas chromatography); Kupfer et al, European Journal
of Clinical Pharmacology, 26 (1984,) pages 753-759 (gas

Wiley & Sons, Inc. New York, 1983, which is incorpo-:
rated herein by reference. It has been discovered that by

liquid chromatograph); Wedlund etal, Clinical Pharma
cology and Therapeutics, Vol. 36, No. 6 (1984), pages

773-780 (high performance liquid chromatography);
Jurima et al, British Journal of Clinical Pharmacology, 19
(1985), pages 483-487 (gas chromatography); and Bi

0nd Edition, J. C. Touchstone and M. F. Dobbins, John

combining high performance thin layer chromatogra
65 phy with the use of probe drugs in determining oxida

tive drug metabolism de?ciencies, a method is provided
for the rapid, ef?cient and inexpensive qualitative as
sessment of oxidative drug metabolism de?ciencies.

3
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These and additional objects and advantages pro
vided by the method of the present invention will be
come more fully understood in view of the following

detailed description.
DETAILED DESCRIPTION
The present invention generally relates to a method

4

has been discovered that the high performance thin
layer chromatography is particularly suitable for re
solving a sample of body ?uid containing a probe drug
and its various metabolites into a series of spots corre

sponding to each component thereby forming a chro

matogram.

and inexpensive phenotyping and pharmacogenetic
screening of subjects. The method comprises analyzing

In a preferred method according to the present inven
tion, the subject under study is
a dosage of
a probe drug. Thereafter, a body ?uid of the subject
which contains the metabolites of the probe drug, for
example urine, is continuously collected, and the col-:

a sample ?uid from the subject which contains metabo~=

lected ?uid is analyzed using high performance thin

for the qualitative assessment of oxidative drug metabo
lism de?ciencies. The method allows for rapid, efficient

lites of a probe drug using high performance thin layer

layer chromatography as discussed above. The high

chromatography. The subject may be human or a non=

performance thin layer chromatography is particularly

human animal and suitably the sample ?uid which is

adapted for resolving the sample body ?uid and separat

analyzed comprises urine. ‘

ing the various metabolites contained therein from one
another and from any unmetabolized probe drug. More
over, once the resolved spots are visualized, visual ob
servation of the thin layer plate will indicate a qualita

As is known in the art, high performance thin layer
chromatography is a speci?c type of adsorption and/or }

partition chromatography wherein the moving phase is

liquid and the stationary phase is a solid adsorbing or 20 tive assessment of the subject’s probe drug metabolism
partitioning material deposited on a ?at supporting
characteristics. Particularly, the chromatography will
surface. The general procedures for high performance
visually indicate whether there is a signi?cantly greater
liquid chromatography are more fully described in
amount of unmetabolized drug contained in the sample
Practice of Thin Layer Chromatography, Second Edition,
whereby the subject is a slow or poor oxidative drug
cited above and incorporated herein by reference. Gen~=
metabolizer, or whether there is a relatively greater

erally, the ?at supporting surface comprises a glass plate

amount of the different metabolites contained in the

although the ?at plate may also be formed of materials
such as ceramic or synthetic plastic materials including

sample whereby the subject is a fast or ef?cient oxida
tive drug metabolizer.

thermosetting and thermoplastic polymers. The adsor~=
A more speci?c embodiment of the present invention
bent and/or partitioning material may comprise any of 30 comprises a method for the qualitative assessment of
the conventional materials known in the art such as
dextromethorphan metabolism in a subject. The method
silica gel, alumina, diatomaceous earth, cellulose, re
comprises analyzing a sample ?uid from the subject
verse phase substances or mixtures thereof. Optionally,
which contains dextromethorphan metabolites using
a binding agent, for example starch or the like, may be
high performance thin layer chromatography as dis
mixed with the adsorbent material to hold it in place on 35 cussed above. Preferably, the subject is administerd a
the ?at plate. The adsorbent material is formed in a thin
dosage of dextromethorphan, a body ?uid of the subject
layer, for example having a thickness of 0.1 to 2.0 milli
which contains dextromethorphan metabolites, prefera
meters, on the ?at plate.
bly urine, is continuously collected, and the collected

Asample which is to be analyzed using high perfor
mance thin layer chromatography is generally mixed

with a solvent and applied as a spot to the adsorbent

surface of the plate. Thus, in accordance with the pres
ent invention, a sample ?uid from the subject which

contains metabolites of the probe drug, preferably

body ?uid is analyzed using high performance thin

layer chromatography.
According to the method of the present invention,
qualitative screening of patients for a de?ciency in oxi

dative drug metabolism, for example the de?ciency
affecting dextromethorphan metabolism, may be per=

urine, is mixed with a solvent and applied as a spot to 45 formed rapidly and economically. Thus, such screen»

the thin layer adsorbent surface deposited on the plate.
With the assistance of the high performance tech
nique and capillary action, a solvent such as Davidow
(composed of ethyl acetate 85 parts, methanol 10 parts
and ammonium hydroxide 5 parts) or any other appro 50
priate solvent systems known to the art for use in thin

layer chromatography migrates up the thin layer of

ings can be performed prior to initiating therapy with
drugs in?uenced by the oxidative drug metabolism
de?ciencies. The following example demonstrates the
suitability of the method of the present invention for

qualitative screening of patients.
EXAMPLE

adsorbent material. Simultaneously, the various constit=
This example demonstrates the method of the present
nents of the sample ?uid migrate along the adsorbent
invention using human subjects. A control urine sample
material to resolve the original spot of mixture into a 55 was taken from each of twelve subjects prior to begin
series of spots corresponding to each or several compo
ning the testing procedure. Each subject then ingested
nents of the mixture. For example, any remainder of the
60mg of dextromethorphan, and complete urine collec
probe drug and any of its di?'erent metabolites con
tion was performed for 8 hours after drug administra
tained in the sample migrate along the adsorbent mate=
tion. Each urine same, including the control samples,
rial to resolve the original spot of sample ?uid into a 60 was analyzed using high performance thin layer chro=
series of spots corresponding to each probe component
matography. Speci?cally, following urine hydrolysis
or several components, thereby separating the drug
and extraction, samples were dissolved in dichloro
from its metabolites. The spots may be visualized by
methane and spotted on a 10 cm high performance thin
spraying them with a suitable color producing agents
layer chromatography silica gel plate. The plate was
such as the known Dragendorff’s reagent followed by
placed in a sealed glass tank containing the mobile phase
5% sodium nitrite spray or any other established visual
solvent (composed of ethylacetate 85 parts: methanol 10
ization reagents known in the art for use with thin layer

pinata-‘normal hydroxide 5 parts) and developed

chromatography. According to the present invention, it

vertically for 5 cm. The plate was removed from the

5
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tank, dried and then sprayed with Lady Tenger reagent
(containing 5 gm bismuth subcarbonate +15 ml hydro

tively assess the metabolite pattern of the subject;
and

chloric acid +15 gm of potassium iodide and 85 ml of
water) followed by a 5% sodium nitrite spray. For

the comparing step is conducted by visually compar
ing the subject's metabolite pattern to a normal

subject's metabolite pattern.

comparison, all samples were also analyzed using high

2. The method of claim 1, wherein

performance liquid chromatography methods. Qualita

the drug is dextramethorfan; and
the sample is urine.

tive examination of the chromatograms resulting from
the high pressure thin layer chromatography clearly

3. The method of claim 1, wherein
the thin layer chromatography is performed on an
adsorbent layer of a material selected from the

distinguished l0 ef?cient or fast metabolizer phenotypes
and 2 slow or poor metabolizer phenotypes in the
group. No interfering substances were detected in any

group consisting of silica gel, alumina, diatoma

of the control urine samples. For con?rmation, accord

ceous earth, cellulose, and mixtures thereof on a

ing to the high performance liquid chromatography

?at plate formed of a material selected from the

method, dextromethorphan and two of its metabolites,
dextrorphan and (+)-3=morphinanol were quanti?ed in
each urine sample using ?uorescence detection. The
ratios between dextromethorphan and the dextrorphan

group consisting of glass, ceramic, and synthetic
plastic materials.

4. The method of claim 1, wherein the collecting,
analyzing and comparing steps are repeated at a speci
metabolite ranged between 0.02 and 0.05 for 10 of the
?ed time interval.
subjects, i.e., the fast or e?icient metabolizers indicated 20 5. In a method for characterizing the oxidative phe=

in the high pressure thin layer chromatography results.
The ratio of dextromethorphan and the dextrorphan

notype of a subject comprising administering to the
subject an amount of a probe drug effective to yield

metabolite for the remaining 2 subjects were 7.5 and

detectable amounts of the drug and its oxidative metab
olites in a ?uid sample of the subject taken at a speci?ed
25 time subsequent to the administration of the drug, col

16.2, thus con?rming the qualitative indication of the 2
slow or poor metabolizer noted from the high perfor
mance thin layer chromatography results. As with the

lecting a ?uid sample from the subject, analyzing the
?uid sample to quantitatively determine the exact ratio
of drug to metabolites present in the sample and com
paring the subject’s ratio to a normal oxidative ratio, the

high pressure thin layer chromatography method, no
interfacing substances were detected in any of the con

trol urines by the high performance liquid chromatogra

phy method. Thus, the method according to the present 30 improvement wherein
the analyzing step is rapidly conducted by high per
invention provides a rapid, efficient and economical

formance thin layer chromatography to qualita

means for qualitatively screening patients for de?cien
cies in oxidative drug metabolism, particularly dextro~

tively assess the metabolite, pattern of the subject;
and

methorphan metabolism.

the comparing step is conducted by visually compar

The preceding Example is set forth to illustrate a
speci?c embodiment of the invention and is not in=
tended to limit the scope of the methods of the present
invention. Additional embodiments and advantages
within the scope of the claimed invention will be appar

ing the subject’s pattern to a normal subject's me

tabolite pattern.
6. The method of claim 5, wherein
the drug is dextramethorfan; and
the sample is urine.

ent to one of ordinary skill in the art.
What is claimed is:

1. In a method for characterizing the oxidative phe
notype of a subject comprising collecting a fluid sample
from the subject, analyzing the sample to quantitatively

7. The method of claim 5, wherein
the thin layer chromatography is performed on an
adsorbent layer of a material selected from the

group consisting of silica gel, alumina, diatoma
45

ceous earth, cellulose, and mixtures thereof on a

drug and comparing the results obtained for the subject
with those obtained for a normal subject subsequent to
the administration of said drug, the improvement
wherein
50

group consisting of glass, ceramic, and synthetic
plastic materials.

determine the presence of oxidative metabolites of a

the analyzing step is rapidly conducted by high per
formance thin layer chromatography to qualita

?at plate formed of a material ‘selected from the
8. The method of claim 5, wherein

the collecting, analyzing and comparing steps are
repeated at a speci?ed'time interval.
3
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